{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=doxorubicin+intravenous&page=2", "query": { "intervention": "doxorubicin intravenous", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 214, "total_pages": 22, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=doxorubicin+intravenous&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=doxorubicin+intravenous&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T09:47:30.213Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02644278", "title": "First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "VX-984 120 mg + PLD 40 mg/m^2", "type": "DRUG" }, { "name": "VX-984 240 mg + PLD 40 mg/m^2", "type": "DRUG" }, { "name": "VX-984 480 mg + PLD 40 mg/m^2", "type": "DRUG" }, { "name": "VX-984 720 mg + PLD 40 mg/m^2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2016-02-29", "completion_date": "2017-10-19", "has_results": true, "last_update_posted_date": "2019-09-09", "last_synced_at": "2026-10-08T09:47:30.213Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Boston, Massachusetts • Nashville, Tennessee + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02644278" }, { "nct_id": "NCT00400946", "title": "05-001: Treatment of Acute Lymphoblastic Leukemia in Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Drug/Agent Toxicity by Tissue/Organ", "Leukemia" ], "interventions": [ { "name": "asparaginase", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "dexrazoxane hydrochloride", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "mercaptopurine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "pegaspargase", "type": "DRUG" }, { "name": "prednisolone", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 800, "start_date": "2005-04", "completion_date": "2019-06", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-08T09:47:30.213Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Rochester, New York + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT00400946" }, { "nct_id": "NCT00455533", "title": "Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ixabepilone", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 384, "start_date": "2007-10", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2016-02-24", "last_synced_at": "2026-10-08T09:47:30.213Z", "location_count": 10, "location_summary": "Palm Springs, California • Coral Spring, Florida • Davie, Florida + 7 more", "locations": [ { "city": "Palm Springs", "state": "California" }, { "city": "Coral Spring", "state": "Florida" }, { "city": "Davie", "state": "Florida" }, { "city": "Lake Worth", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00455533" }, { "nct_id": "NCT01593228", "title": "Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Iniparib (SAR240550/BSI-201)", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Doxorubicin HCL liposome injection", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2012-05", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2017-09-19", "last_synced_at": "2026-10-08T09:47:30.213Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Santa Maria, California • Vallejo, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Santa Maria", "state": "California" }, { "city": "Vallejo", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01593228" }, { "nct_id": "NCT00043979", "title": "Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "F-18 Fluorodeoxyglucose", "type": "DRUG" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell donation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "5 Years to 35 Years" }, "enrollment_count": 60, "start_date": "2002-09-19", "completion_date": "2011-12-14", "has_results": true, "last_update_posted_date": "2017-05-31", "last_synced_at": "2026-10-08T09:47:30.213Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00043979" }, { "nct_id": "NCT06312176", "title": "A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1200, "start_date": "2024-04-14", "completion_date": "2031-04-12", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-08T09:47:30.213Z", "location_count": 46, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Fullerton, California + 38 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06312176" }, { "nct_id": "NCT01849874", "title": "A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Low-grade Serous Ovarian Cancer", "Low-grade Serous Fallopian Tube Cancer", "Low-grade Serous Peritoneal Cancer" ], "interventions": [ { "name": "MEK162, MEK inhibitor; oral", "type": "DRUG" }, { "name": "Physician's choice chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 341, "start_date": "2013-06-27", "completion_date": "2022-08-23", "has_results": true, "last_update_posted_date": "2023-10-30", "last_synced_at": "2026-10-08T09:47:30.213Z", "location_count": 77, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 37 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01849874" }, { "nct_id": "NCT00000689", "title": "Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin", "HIV Infections" ], "interventions": [ { "name": "Bleomycin sulfate", "type": "DRUG" }, { "name": "Vincristine sulfate", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Leucovorin calcium", "type": "DRUG" }, { "name": "Sargramostim", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 18, "start_date": null, "completion_date": "1991-03", "has_results": false, "last_update_posted_date": "2021-11-02", "last_synced_at": "2026-10-08T09:47:30.213Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000689" }, { "nct_id": "NCT01414855", "title": "A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, B-Cell" ], "interventions": [ { "name": "obinutuzumab", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2011-08-31", "completion_date": "2016-12-23", "has_results": true, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-08T09:47:30.213Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Encinitas, California • Aurora, Colorado + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Encinitas", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Norwalk", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01414855" }, { "nct_id": "NCT01510184", "title": "Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-cell Lymphoma", "Follicle Center Lymphoma" ], "interventions": [ { "name": "Zevalin", "type": "DRUG" }, { "name": "Y-90-Zevalin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "In-111 Zevalin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 79, "start_date": "2012-04-19", "completion_date": "2014-10-23", "has_results": true, "last_update_posted_date": "2021-12-16", "last_synced_at": "2026-10-08T09:47:30.213Z", "location_count": 28, "location_summary": "Casa Grande, Arizona • Berkeley, California • Duarte, California + 24 more", "locations": [ { "city": "Casa Grande", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01510184" } ] }